Table of Contents Author Guidelines Submit a Manuscript
Malaria Research and Treatment
Volume 2012 (2012), Article ID 257986, 5 pages
http://dx.doi.org/10.1155/2012/257986
Research Article

Subacute Therapeutic Dosing of Artemether-Lumefantrine and Artesunate-Amodiaquine Combination Preserves Plasma Cholesterol, Renal Antioxidant Status, and Organ Weights in Rats

1Department of Chemical Sciences, Redeemer’s University, PMB 2011, Mowe, Ogun, Nigeria
2Department of Pharmacology, Olabisi Onabanjo University, PMB 2002, Ago-Iwoye, Ogun, Nigeria

Received 26 December 2011; Accepted 30 May 2012

Academic Editor: Neena Valecha

Copyright © 2012 Chiagoziem A. Otuechere et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Recent instances of breakdowns of malaria control programs and the constant emergence of drug-resistant parasites to monotherapies have shored up the use of artemisinin-based combination therapy (ACT) as the malaria therapy of choice. We evaluated a subacute therapeutic dosing of artemether-lumefantrine and artesunate-amodiaquine on plasma cholesterol, renal antioxidants, and organ weights in rats. Sixteen albino rats were grouped into three. Group A ( 𝑛 = 5 ) served as the control. Groups B ( 𝑛 = 6 ) and C ( 𝑛 = 5 ) were administered, twice daily, oral therapeutic doses of artemether-lumefantrine (1.14/6.86 mg/kg/d) and artesunate-amodiaquine (2.86/8.58 mg/kg/d), respectively, for seven days. From our results, ACTs did not significantly ( 𝑃 > 0 . 0 5 ) alter catalase, superoxide dismutase, glutathione S-transferase, myeloperoxidase, and total glutathione levels when compared with the control. Plasma total cholesterol levels also decreased insignificantly ( 𝑃 > 0 . 0 5 ). Organ-system weights were not significantly ( 𝑃 > 0 . 0 5 ) different from control rats. Artesunate-amodiaquine, but not artemether-lumefantrine, significantly increased ( 𝑃 < 0 . 0 5 ) lactate dehydrogenase activity and also afforded a 27.2% decrease in heart weight when compared with control. Also, both ACTs increased ( 𝑃 < 0 . 0 5 ) lipid peroxidation. Overall, artesunate-amodiaquine and artemether-lumefantrine may preserve renal antioxidants and organ weights in vivo. However, caution is required above therapeutic indications or in chronic doses as this may predispose to renal oxidative stress.